Hydrocortisone

證據等級: L5

預測適應症: 10 個

Hydrocortisone: From Anti-inflammatory/Adrenal Insufficiency to Alopecia Areata

One-Sentence Summary

Hydrocortisone is a naturally occurring glucocorticoid (cortisol) widely used for anti-inflammatory therapy and adrenal insufficiency replacement. The TxGNN model predicts it may be effective for Alopecia Areata, with 4 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Anti-inflammatory, immunosuppressive, and adrenal insufficiency replacement therapy (not currently registered in the Philippines)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Hydrocortisone (cortisol) is the primary endogenous glucocorticoid produced by the adrenal cortex. It exerts potent anti-inflammatory and immunosuppressive effects by binding to intracellular glucocorticoid receptors (GR), which in turn inhibit NF-κB signaling and suppress the production of pro-inflammatory cytokines including IFN-γ, IL-2, IL-15, and TNF-α. Clinically, hydrocortisone is used both as physiological replacement in adrenal insufficiency and as pharmacological therapy for a wide range of inflammatory and autoimmune conditions.

Alopecia areata (AA) is a T-cell-mediated autoimmune disease in which CD8⁺NKG2D⁺ T lymphocytes attack the hair follicle immune privilege zone, causing patchy, non-scarring hair loss. The collapse of hair follicle immune privilege involves local upregulation of IFN-γ and IL-15 — precisely the cytokines that glucocorticoids suppress. Corticosteroids (topical, intralesional, and systemic) have been a cornerstone of AA treatment for over 60 years, and hydrocortisone specifically has been studied in this context since the 1950s.

As a low-to-moderate potency corticosteroid, hydrocortisone is particularly suited for paediatric and mild AA cases where high-potency steroids may carry disproportionate risks. A completed Phase 3 RCT (NCT01453686, published as PMID 24226568 in JAMA Dermatology) directly compared hydrocortisone 1% cream with clobetasol propionate 0.05% cream in children with AA. Multiple earlier publications (dating back to 1956) document clinical responses to intradermal hydrocortisone injections in AA. The mechanistic rationale is direct and well established: suppression of the autoimmune T-cell response that drives hair follicle destruction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453686	Phase 3	Completed	41	Direct RCT comparing hydrocortisone 1% cream vs clobetasol 0.05% cream in children with AA. Published in JAMA Dermatology (2014). Highest-grade direct clinical evidence.
NCT00484679	Phase 2	Completed	18	Evaluated adrenal gland function after intralesional triamcinolone acetonide injections in AA patients. Provides corticosteroid-class safety data on HPA axis suppression.
NCT06551818	N/A	Not Yet Recruiting	72	Prospective four-arm, double-blind, dose-response study of hair growth products in androgenic alopecia (Grade I–III). Potential corticosteroid comparator arm.
NCT04343560	N/A	Completed	380	Assessed effects of abnormal steroid metabolism on bone density and body composition. Provides long-term corticosteroid safety context for AA patients.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24226568	2014	RCT	JAMA Dermatology	Clobetasol 0.05% vs hydrocortisone 1% cream for AA in children — direct head-to-head RCT providing the highest level of evidence.
36718837	2023	Systematic Review / Meta-analysis	J Cosmet Dermatol	Systematic review of fractional laser for AA; contextualises the therapeutic landscape including corticosteroid comparators.
38501938	2024	Clinical Study	Clin Exp Dermatol	Retrospective analysis of topical corticosteroid treatment under occlusion for severe AA (including AT/AU) in children. Supports corticosteroid efficacy in paediatric populations.
13368875	1956	Case Series	Medical Times	Seminal early report on treatment of AA (partialis and totalis) with cortisone, hydrocortisone, prednisone, and prednisolone.
13610145	1958	Clinical Report	Der Hautarzt	Hair regrowth in AA and alopecia maligna following intracutaneous hydrocortisone injection.
5989830	1966	Clinical Report	Vestnik Dermatol Venerol	Treatment of AA and alopecia totalis patients with intradermal hydrocortisone injections.
14158891	1963	Clinical Report	Actas Dermo-Sifiliogr	Treatment of AA with intradermal hydrocortisone injections.
28516731	2017	Review	JEADV	Challenges the HPA axis hyperactivity hypothesis in AA; examines cortisol and MSH production in affected patients.
29227263	2017	Review	Georgian Med News	Assessed cortisol/insulin as adaptive hormones and dermatological quality of life in 48 AA patients vs controls.
39506493	2025	Exploratory Study	J Cosmet Dermatol	Demonstrated link between chronic psychological stress, cortisol release, and dermatoses including AA at the cellular level.

Philippines Market Information

Hydrocortisone is currently not registered with the Philippines FDA. No authorization records are available. To proceed with repurposing, a new drug application or importation pathway would need to be explored.

Safety Considerations

Please refer to the package insert for safety information. Key safety data gaps include TFDA label warnings/contraindications and drug-drug interaction profiles (classified as Blocking severity in the data gap assessment).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Hydrocortisone has direct Phase 3 RCT evidence and over 60 years of published clinical experience supporting its use in alopecia areata. The mechanistic rationale is unambiguous — glucocorticoid-mediated suppression of T-cell autoimmune attack on hair follicles — and corticosteroids are already a standard-of-care treatment class for this indication. The TxGNN prediction score of 99.97% aligns well with the established clinical evidence base.

To proceed, the following is needed:

Safety data (Blocking): Obtain Philippines FDA or reference-country drug label for warnings, contraindications, and precautions
Mechanism of action detail: Retrieve complete MOA data from DrugBank (DB00741) to strengthen mechanistic documentation
Route compatibility assessment: Determine optimal formulation (topical cream, intralesional injection, or systemic) for the AA indication
Regulatory pathway: Assess Philippines FDA registration or importation pathway, given the drug is not currently marketed locally
Paediatric safety monitoring plan: Given that the pivotal RCT was conducted in children, develop age-appropriate safety monitoring protocols (HPA axis suppression, skin atrophy)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.